Clinical applications of non-antimicrobial tetracyclines in dermatology

Pharmacological Research

Volumn 63, Issue 2, 2011, Pages 130-145

  Monk, Edward ^a   Shalita, Alan ^b   Siegel, Daniel Mark ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b SUNY Downstate Medical Center   (United States)

Author keywords

Chemically modified; Dermatology; Doxycycline; Minocycline; MMP; Non antimicrobial; Tetracycline

Indexed keywords

ANTIRETROVIRUS AGENT; CORTICOSTEROID; DEMECLOCYCLINE; DOXYCYCLINE; INCYCLINIDE; MATRIX METALLOPROTEINASE; METRONIDAZOLE; MINOCYCLINE; NICOTINAMIDE; PLACEBO; PREDNISONE; REACTIVE OXYGEN METABOLITE; TETRACYCLINE DERIVATIVE;

ACNE; ARTICLE; AUTOIMMUNE DISEASE; BULLOUS PEMPHIGOID; CHRONIC WOUND; DEMODEX; DEMODEX FOLLICULORUM; DERMATOLOGY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DYSKERATOSIS; EPIDERMOLYSIS BULLOSA HEREDITARIA; ERYTHEMATOSQUAMOUS SKIN DISEASE; FOREIGN BODY GRANULOMA; HELICOBACTER PYLORI; HUMAN; HYPERPIGMENTATION; KAPOSI SARCOMA; LICHENOID ERUPTION; LOW DRUG DOSE; MAST CELL; MOLECULAR PATHOLOGY; NONHUMAN; ONYCHOLYSIS; OROFACIAL GRANULOMATOSIS; PEMPHIGUS VULGARIS; PERIODONTITIS; PHOTOSENSITIVITY; PHOTOTOXICITY; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PSORIASIS; ROSACEA; SARCOIDOSIS; SKIN DISEASE; SKIN INJURY;

EID: 79251607712     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.10.007     Document Type: Article

References (245)

1. G.H. Crawford, M.T. Pelle, W.D. James, and I. Rosacea: Etiology, pathogenesis, and subtype classification J Am Acad Dermatol 51 2004 327 341
2. K. Aroni, E. Tsagroni, A.C. Lazaris, E. Patsouris, and E. Agapitos Rosacea: a clinicopathological approach Dermatology 209 3 2004 177 182
3. M.T. Pelle, G.H. Crawford, and W.D. James Rosacea: II. Therapy J Am Acad Dermatol 51 October (4) 2004 499 512
4. J. Sanchez, A.L. Somolinos, P.I. Almodóvar, G. Webster, M. Bradshaw, and C. Powala A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in thetreatment of rosacea J Am Acad Dermatol 53 November (5) 2005 791 797
5. J.Q. Del Rosso, J. Schlessinger, and P. Werschler Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea J Drugs Dermatol 7 June (6) 2008 573 576
6. J.Q. Del Rosso, G.F. Webster, M. Jackson, M. Rendon, P. Rich, and H. Torok Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea J Am Acad Dermatol 56 May (5) 2007 791 802
7. Lehmann P, Rosacea. Clinical features, pathogenesis and therapy. Hautarzt. 2005 September (1);56(9):871-85 [quiz 886-7].
8. J.A. Majeski, M.A. McClellan, and J.W. Alexander Effect of antibiotics on the in vitro neutrophil chemotactic response Am Surg 42 October (10) 1976 785 788
9. N.B. Esterly, N.L. Furey, and L.E. Flanagan The effect of antimicrobial agents on leukocyte chemotaxis J Invest Dermatol 70 January (1) 1978 51 55
10. W.L. Gabler, and H.R. Creamer Suppression of human neutrophil functions by tetracyclines J Periodontal Res 26 January (1) 1991 52 58
11. N.B. Esterly, J.S. Koransky, N.L. Furey, and M. Trevisan Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy Arch Dermatol 120 October (10) 1984 1308 1313
12. A. Jain, L. Sangal, E. Basal, G.P. Kaushal, and S.K. Agarwal Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils Dermatol Online J 8 October (2) 2002 2
13. L.M. Golub, H.M. Lee, M.E. Ryan, W.V. Giannobile, J. Payne, and T. Sorsa Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms Adv Dent Res 12 November (2) 1998 12 26
14. T. Krakauer, and M. Buckley Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines Antimicrob Agents Chemother 47 November (11) 2003 3630 3633
15. A. Solomon, M. Rosenblatt, D. Li, D. Monroy, Z. Ji, and B.L. Lokeshwar Doxycycline inhibition of interleukin-1 in the corneal epithelium Am J Ophthalmol 130 November (5) 2000 688
16. J. Cazalis, S. Tanabe, G. Gagnon, T. Sorsa, and D. Grenier Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood Inflammation 32 April (2) 2009 130 137
17. L. Shapira, W.A. Soskolne, Y. Houri, V. Barak, A. Halabi, and A. Stabholz Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion Infect Immun 64 March (3) 1996 825 828
18. W. Hornebeck, H. Emonard, F.X. Maquart, and G. Bellon Proteolysis directed by the extracellular matrix J Soc Biol 197 1 2003 25 30
19. S. Lee, S.M. Jilani, G.V. Nikolova, D. Carpizo, and M.L. Iruela-Arispe Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors J Cell Biol 169 May (4) 2005 681 691
20. P.D. Crowe, B.N. Walter, K.M. Mohler, C. Otten-Evans, R.A. Black, and C.F. Ware A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes J Exp Med 181 March (3) 1995 1205 1210
21. K. Kessenbrock, V. Plaks, and Z. Werb Matrix metalloproteinases: regulators of the tumor microenvironment Cell 141 April (1) 2010 52 67
22. G.F. Webster, S.M. Toso, and L. Hegemann Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C Arch Dermatol 130 June (6) 1994 748 752
23. I. Dobrić, A. Basta-Juzbasić, and M. Skerlev The effectiveness of tetracycline inthe treatment of rosacea associated with epithelioid granulomas Acta Med Iugosl 43 2 1989 127 136
24. Naito Y, Takagi T, Yoshikawa T. Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease. J Gastroenterol. 2007;42(October (10)):787-98 [Epub 2007 October 15. Review].
25. F. Martinon Signaling by ROS drives inflammasome activation Eur J Immunol 40 March (3) 2010 616 619
26. C.N. Young, J.I. Koepke, L.J. Terlecky, M.S. Borkin, L. Boyd Savoy, and S.R. Terlecky Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease J Invest Dermatol 128 November (11) 2008 2606 2614
27. G.J. Quinlan, and J.M. Gutteridge Hydroxyl radical generation by the tetracycline antibiotics with free radical damage to DNA, lipids and carbohydrate in the presence of iron and copper salts Free Radic. Biol. Med. 5 5-6 1988 341 348
28. O. Bakar, Z. Demiray, M. Yuksel, G. Haklar, and Y. Sanisoglu The effect of azithromycin on reactive oxygen species in rosacea Clin Exp Dermatol 32 March (2) 2007 197 200
29. Korting HC, Schöllmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol. 2009; 22(6):287-94 [Epub 2009 September 25. Review].
30. Y. Miyachi, A. Yoshioka, S. Imamura, and Y. Niwa Effect of antibiotics on the generation of reactive oxygen species J Invest Dermatol 86 April (4) 1986 449 453
31. H. Akamatsu, M. Asada, J. Komura, Y. Asada, and Y. Niwa Effect of doxycycline on the generation of reactive oxygen species: a possible mechanism of action of acne therapy with doxycycline Acta Derm Venereol 72 3 1992 178 179
32. A.R. Amin, R.N. Patel, G.D. Thakker, C.J. Lowenstein, M.G. Attur, and S.B. Abramson Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines FEBS Lett. 410 June (2-3) 1997 259 264
33. R.L. Kraus, R. Pasieczny, K. Lariosa-Willingham, M.S. Turner, A. Jiang, and J.W. Trauger Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity J Neurochem 94 August (3) 2005 819 827
34. Lin S, Wei X, Xu Y, Yan C, Dodel R, Zhang Y, Liu J, Klaunig JE, Farlow M, Du Y. Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons. Life Sci. 2003 (February).
35. K. Faust, S. Gehrke, Y. Yang, L. Yang, M.F. Beal, and B. Lu Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease BMC Neurosci September (10) 2009 109
36. W.D. Cornwell, V. Kim, C. Song, and T.J. Rogers Pathogenesis of inflammation and repair in advanced COPD Semin. Respir. Crit. Care Med. 31 June (3) 2010 257 266
37. M. Wasil, B. Halliwell, and C.P. Moorhouse Scavenging of hypochlorous acid by tetracycline, rifampicin and some other antibiotics: a possible antioxidant action of rifampicin and tetracycline? Biochem. Pharmacol. 37 February (4) 1988 775 778
38. M. Whiteman, and B. Halliwell Prevention of peroxynitrite-dependent tyrosine nitration and inactivation of alpha1-antiproteinase by antibiotics Free Radic Res 26 January (1) 1997 49 56
39. H.M. van Barr, P.C. van de Kerkhof, P.D. Mier, and R. Happle Tetracyclines are potent scavengers of the superoxide radical Br J Dermatol 117 July (1) 1987 131 132
40. H. Trachtman, S. Futterweit, R. Greenwald, S. Moak, P. Singhal, and N. Franki Chemically modified tetracyclines inhibit inducible nitric oxide synthase expression and nitric oxide production in cultured rat mesangial cells Biochem Biophys Res Commun 229 December (1) 1996 243 248 (Pubitemid 27013738)
41. A.R. Amin, M.G. Attur, G.D. Thakker, P.D. Patel, P.R. Vyas, and R.N. Patel A novel mechanism of action of tetracyclines: effects on nitric oxide synthases Proc Natl Acad Sci U S A 93 November (24) 1996 14014 14019
42. M. Whiteman, H. Kaur, and B. Halliwell Protection against peroxynitrite dependent tyrosine nitration and alpha 1-antiproteinase inactivation by some anti-inflammatory drugs and by the antibiotic tetracycline Ann Rheum Dis 55 June (6) 1996 383 387
43. M. Tomás-Camardiel, I. Rite, A.J. Herrera, R.M. de Pablos, J. Cano, and A. Machado Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system Neurobiol Dis 16 June (1) 2004 190 201
44. A.N. Olenik, and L.M. Ovsiannikova Mechanism of the pro-oxidant activity of tetracycline Antibiotiki 28 November (11) 1983 845 848
45. N.P. Skakun, and IIu. Vysotski Effect of tetracycline antibiotics on lipid peroxidation Antibiotiki 27 9 1982 684 687
46. IuM. Petrenko Tetracyclines as components of radical-generating systems Antibiot Khimioter 39 July (7) 1994 10 14
47. I.U. Petrenko, VIu Titov, and IuA. Vladimirov Generation of active forms of oxygen by antibiotics of the tetracycline series during tetracycline catalysis of oxidation of ferrous iron Antibiot Khimioter 40 February (2) 1995 3 8
48. M. Ahuja, M. Bishnoi, and K. Chopra Protective effect of minocycline, a semi-synthetic second-generation tetracycline against 3-nitropropionic acid (3-NP)-induced neurotoxicity Toxicology 244 February (2-3) 2008 111 122
49. J. Glette, and S. Sandberg Phototoxicity of tetracyclines as related to singlet oxygen production and uptake by polymorphonuclear leukocytes Biochem Pharmacol 35 September (17) 1986 2883 2885
50. K. Aroni, E. Tsagroni, N. Kavantzas, E. Patsouris, and E. Ioannidis A study of the pathogenesis of rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process Arch Dermatol Res 300 March (3) 2008 125 131
51. J.R. Smith, V.B. Lanier, R.M. Braziel, K.M. Falkenhagen, C. White, and J.T. Rosenbaum Expression of vascular endothelial growth factor and its receptors in rosacea Br J Ophthalmol 91 February (2) 2007 226 229
52. C.Z. Lee, B. Xu, T. Hashimoto, C.E. McCulloch, G.Y. Yang, and W.L. Young Doxycycline suppresses hyperstimulation of cerebral matrix metalloproteinase-9 and angiogenesis induced by focal of vascular endothelial growth factor in a mouse model Stroke 35 July (7) 2004 1715 1719
53. Y. Tang, M.T. Nakada, P. Kesavan, F. McCabe, H. Millar, and P. Rafferty Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases Cancer Res 65 April (8) 2005 3193 3199
54. S. Samtani, J. Amaral, M.M. Campos, R.N. Fariss, and S.P. Becerra Doxycycline-mediated inhibition of choroidal neovascularization Invest Ophthalmol Vis Sci 50 November (11) 2009 5098 5106
55. S. Mariotto, Y. Suzuki, T. Persichini, M. Colasanti, H. Suzuki, and O. Cantoni Cross-talk between NO and arachidonic acid in inflammation Curr Med Chem 14 18 2007 1940 1944
56. P. D'Agostino, V. Ferlazzo, S. Milano, M. La Rosa, G. Di Bella, and R. Caruso Anti-inflammatory effects of chemically modified tetracyclines by the inhibition of nitric oxide and interleukin-12 synthesis in J774 cell line Int Immunopharmacol 1 September (9-10) 2001 1765 1776
57. A. Shalita, and J. Leyden Mechanism-based selection of pharmacologic agents for rosacea Cutis 73 Jan (Suppl. 1) 2004 15 18
58. S.K. Jung, K.W. Lee, H.Y. Kim, M.H. Oh, S. Byun, and S.H. Lim Myricetin suppresses UVB-induced wrinkle formation and MMP-9 expression by inhibiting Raf Biochem Pharmacol 79 May (10) 2010 1455 1461
59. T. Quan, Z. Qin, W. Xia, Y. Shao, J.J. Voorhees, and G.J. Fisher Matrix-degrading metalloproteinases in photoaging J Investig Dermatol Symp Proc 14 August (1) 2009 20 24
60. S. Xu, and X. Cao Interleukin-17 and its expanding biological functions Cell MolImmunol 7 May (3) 2010 164 174 [Epub 2010 April 12]
61. J.D. Raffetto Dermal pathology, cellular biology, and inflammation in chronic venous disease Thromb Res 123 Suppl. 4 2009 S66 71
62. M. Määttä, O. Kari, T. Tervahartiala, S. Peltonen, M. Kari, and M. Saari Tear fluid levels of MMP-8 are elevated in ocular rosacea - treatment effect of oraldoxycycline Graefes Arch Clin Exp Ophthalmol 244 August (8) 2006 957 962
63. A. Iovieno, A. Lambiase, A. Micera, B. Stampachiacchiere, R. Sgrulletta, and S. Bonini In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis Eur J Ophthalmol 19 September-October (5) 2009 708 716
64. M. Schneir, N. Ramamurthy, and L. Golub Minocycline-treatment of diabetic rats normalizes skin collagen production and mass: possible causative mechanisms Matrix 10 May (2) 1990 112 123
65. R.G. Craig, Z. Yu, L. Xu, R. Barr, N. Ramamurthy, and J. Boland A chemically modified tetracycline inhibits streptozotocin-induced diabetic depression of skin collagen synthesis and steady-state type I procollagen mRNA Biochim Biophys Acta 1402 April (3) 1998 250 260
66. R. Gapski, H. Hasturk, T.E. Van Dyke, R.J. Oringer, S. Wang, and T.M. Braun Systemic MMP inhibition for periodontal wound repair: results of a multi-centreandomized-controlled clinical trial J Clin Periodontol 36 February (2) 2009 149 156
67. R.A. Ashley Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD Clinical Research Team Ann N Y Acad Sci 878 June 1999 335 346
68. J.G. Caton, S.G. Ciancio, T.M. Blieden, M. Bradshaw, R.J. Crout, and A.F. Hefti Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adultperiodontitis J Periodontol 71 April (4) 2000 521 532
69. R.R. Bonamigo, L. Bakos, M. Edelweiss, and A. Cartell Could matrix metalloproteinase-9 be a link between Demodex folliculorum and rosacea? J Eur Acad Dermatol Venereol 19 September (5) 2005 646 647
70. F. Forton, and B. Seys Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy Br J Dermatol 128 1993 650 659
71. H. Moravvej, M. Dehghan-Mangabadi, M.R. Abbasian, and G. Meshkat-Razavi Association of rosacea with demodicosis Arch Iran Med 10 April (2) 2007 199 203
72. J.R.H. Andrews The prevalence of hair follicle mites in Caucasian New Zealanders N Z Med J 95 1982 451 453
73. R. Reichers, and W.W. Kopf Cutaneous infestation with Demodex folliculorum in man J Invest Dermatol 52 1969 103 106
74. A.A. Ramlet, and G. Perroulaz Rosacea: histopathologic study of 75 cases Ann Dermatol Venereol 115 1988 801 806
75. A. Szlachcic, Z. Sliwowski, and E. Karczewska Helicobacter pylori infection and its eradication in rosacea J Physiol Parmacol 50 1999 777 786 (Pubitemid 30090011)
76. V.K. Sharma, A. Lynn, M. Kaminski, R. Vasudeva, and C.W. Howden A study of the prevalence of Helicobacter pylori infection and other markers of upper gastrointestinal tract disease in patients with rosacea Am J Gastroenterol 93 February (2) 1998 220 222
77. M.P. Jones, A.L. Knable Jr., M.J. White, and S.J. Durning Helicobacter pylori in rosacea: lack of an association Arch Dermatol 134 April (4) 1998 511
78. T.V. Budkevich, A.V. El'skaya, and K.H. Nierhaus Features of 80S mammalian ribosome andits subunits Nucleic Acids Res 36 August (14) 2008 4736 4744
79. E. Bonnar, P. Eustace, and F.C. Powell The Demodex mite population in rosacea J Am Acad Dermatol 28 1993 443 448
80. M. Akyildiz, S. Akay, A. Musoglu, M. Tuncyurek, and A. Aydin The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication Eur J Intern Med 20 January (1) 2009 53 57
81. K. McKeage, and E.D. Deeks Doxycycline 40 mg Capsules (30 mg Immediate-Release/10 mg delayed-release beads): anti-inflammatory dose in rosacea Am J Clin Dermatol 11 3 2010 217 222
82. A.D. Haffajee, M. Patel, and S.S. Socransky Microbiological changes associated with four different periodontal therapies for the treatment of chronic periodontitis Oral Microbiol Immunol 23 April (2) 2008 148 157
83. J.F. Fowler Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea J Drugs Dermatol 6 June (6) 2007 641 645
84. W.C. King, and M.A. Forbes Jr. The use of tetra(cycline in the treatment of acne vulgaris: a clinical study South Med J 49 August (8) 1956 875 879
85. R.K. Freinkel, J.S. Strauss, S.Y. Yip, and P.E. Pochi Effect of tetracycline on the composition of sebum in acne vulgaris N Engl J Med 273 October (16) 1965 850 854
86. G.W. Beveridge, and E.W. Powell Sebum changes in acne vulgaris treated with tetracycline Br J Dermatol 81 July (7) 1969 525 527
87. M. Gloor, M. Kionke, and H.C. Friederich Effect of tetracycline therapy in acne vulgaris on amount and composition of skin surface lipids in various dosages. Gas chromatographic studies of its action mechanism Arch Dermatol Forsch 243 4 1972 335 340
88. W.J. Cunliffe, R.A. Forster, N.D. Greenwood, C. Hetherington, K.T. Holland, and R.L. Holmes Tetracycline and acne vulgaris: a clinical and laboratory investigation Br Med J 4 November (5888) 1973 332 335
89. G.S. Hassing Inhibition of Corynebacterium acnes lipase by tetracycline J Invest Dermatol 56 March (3) 1971 189 192
90. R.E. Kellum, K. Strangfeld, and L.F. Ray Acne vulgaris. Studies in pathogenesis: triglyceride hydrolysis by Corynebacterium acnes in vitro Arch Dermatol 101 January (1) 1970 41 47
91. K. Weaber, R. Freedman, and W.W. Eudy Tetracycline inhibition of a lipase from Corynebacterium acnes Appl Microbiol 21 April (4) 1971 639 642
92. W.L. Lee, A.R. Shalita, K. Suntharalingam, and S.M. Fikrig Neutrophil chemotaxis by Propionibacterium acnes lipase and its inhibition Infect Immun 35 January (1) 1982 71 78
93. Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, Shalita AR,Lozada VT, Berson D, Finlay A, Goh CL, Herane MI, Kaminsky A, Kubba R, Layton A, Miyachi Y, Perez M, Martin JP, Ramos-E-Silva M, See JA, Shear N, Wolf J Jr; Global, Alliance to Improve Outcomes in Acne. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60(May (5 Suppl.)):S1-50.
94. A.M. Kligman, V.R. Wheatley, and O.H. Mills Comedogenicity of human sebum Arch Dermatol 102 September (3) 1970 267 275
95. T. Nakatsuji, M.C. Kao, L. Zhang, C.C. Zouboulis, R.L. Gallo, and C.M. Huang Sebum free fatty acids enhance the innate immune defense of human sebocytes by upregulating beta-defensin-2 expression J Invest Dermatol 130 April (4) 2010 985 994
96. J.J. Leyden New understandings of the pathogenesis of acne J Am Acad Dermatol 32 May (5 Pt 3) 1995 S15 25 [review]
97. J. Kim, M.T. Ochoa, S.R. Krutzik, O. Takeuchi, S. Uematsu, and A.J. Legaspi Activationof toll-like receptor 2 in acne triggers inflammatory cytokine responses J Immunol 169 August (3) 2002 1535 1541
98. Simonart T, Dramaix M, De Maertelaer V. Efficacy of tetracyclines in the treatment of acne vulgaris: a review. Br J Dermatol 2008;158(February (2)):208-16 [Epub 2007 November 6; review].
99. G.F. Webster, J.J. Leyden, K.J. McGinley, and W.P. McArthur Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacteriumacnes by subminimal inhibitory concentrations of tetracycline, ampicillin,minocycline, and erythromycin Antimicrob Agents Chemother 21 May (5) 1982 770 772
100. C. Ishikawa, T. Tsuda, H. Konishi, N. Nakagawa, and K. Yamanishi Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes Antimicrob Agents Chemother 53 May (5) 2009 1760 1765
101. Trivedi NR, Gilliland KL, Zhao W, Liu W, Thiboutot DM. Gene array expressionprofiling in acne lesions reveals marked upregulation of genes involved ininflammation and matrix remodeling. J Invest Dermatol 2006 May;126(5):1071-9 [Erratum in: J Invest Dermatol 2007 July;127(7):1825].
102. Ishikawa C, Tsuda T, Konishi H, Nakagawa N, Yamanishi K. Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes. Antimicrob Agents Chemother 2009 May;53(5):1760-5 [Epub 2009 March 2].
103. R. Stillie, S.M. Farooq, J.R. Gordon, and A.W. Stadnyk The functional significance behind expressing two IL-8 receptor types on PMN J Leukoc Biol 86 September (3) 2009 529 543
104. M. Ottaviani, T. Alestas, E. Flori, A. Mastrofrancesco, C.C. Zouboulis, and M. Picardo Peroxidated squalene induces the production of inflammatory mediators in HaCaT keratinocytes: a possible role in acne vulgaris J Invest Dermatol 126 November (11) 2006 2430 2437
105. T. Tochio, H. Tanaka, S. Nakata, and H. Ikeno Accumulation of lipid peroxide in the content of comedones may be involved in the progression of comedogenesis and inflammatory changes in comedones J Cosmet Dermatol 8 June (2) 2009 152 158
106. P.A. Grange, C. Chéreau, J. Raingeaud, C. Nicco, B. Weill, and N. Dupin Production of superoxide anions by keratinocytes initiates P. acnes-induced inflammation of the skin PLoS Pathog 5 July (7) 2009
107. Sarici G, Cinar S, Armutcu F, Altinyazar C, Koca R, Tekin N. Oxidative stress in acne vulgaris. J Eur Acad Dermatol Venereol 2009 November 23.
108. T. Alestas, R. Ganceviciene, S. Fimmel, K. Müller-Decker, and C.C. Zouboulis Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands J Mol Med 84 January (1) 2006 75 87
109. W. Pruzanski, E. Stefanski, P. Vadas, T.F. McNamara, N. Ramamurthy, and L.M. Golub Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2 J Rheumatol 25 September (9) 1998 1807 1812
110. W. Pruzanski, R.A. Greenwald, I.P. Street, F. Laliberte, E. Stefanski, and P. Vadas Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline Biochem Pharmacol 44 September (6) 1992 1165 1170
111. Y. Song, E.Q. Wei, W.P. Zhang, Q.F. Ge, J.R. Liu, and M.L. Wang Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation Brain Res 1085 April (1) 2006 57 67
112. I. Kurokawa, F.W. Danby, Q. Ju, X. Wang, L.F. Xiang, and L. Xia New developmentsin our understanding of acne pathogenesis and treatment Exp Dermatol 18 October (10) 2009 821 832
113. Toyoda M, Morohashi M., Pathogenesis of acne. Med Electron Microsc. 2001; 34(March (1)):29-40.
114. A.H. Jeremy, D.B. Holland, S.G. Roberts, K.F. Thomson, and W.J. Cunliffe Inflammatory events are involved in acne lesion initiation J Invest Dermatol 121 July (1) 2003 20 27
115. S. Pastore, F. Mascia, V. Mariani, and G. Girolomoni The epidermal growth factor receptor system in skin repair and inflammation J Invest Dermatol 128 June (6) 2008 1365 1374 [Epub 2007 November 29]
116. R. Guy, and T. Kealey The effects of inflammatory cytokines on the isolated human sebaceous infundibulum J Invest Dermatol 110 April (4) 1998 410 415
117. R.W. Groves, H. Mizutani, J.D. Kieffer, and T.S. Kupper Inflammatory skin disease in transgenic mice that express high levels of interleukin 1 alpha in basal epidermis Proc Natl Acad Sci U S A 92 December (25) 1995 11874 11878
118. R. Guy, and T. Kealey Modelling the infundibulum in acne Dermatology 196 1 1998 32 37
119. Lee SE, Kim JM, Jeong SK, Jeon JE, Yoon HJ, Jeong MK, Lee SH. Protease-activated receptor-2 mediates the expression of inflammatory cytokines, antimicrobial peptides, and matrix metalloproteinases in keratinocytes in response to Propionibacterium acnes. Arch Dermatol Res 2010 August 10.
120. W.J. Lee, H.D. Jung, H.J. Lee, B.S. Kim, S.J. Lee, and W. Kim do Influence of substance-P on cultured sebocytes Arch Dermatol Res 300 July (6) 2008 311 316 [Epub April 22]
121. R.F. O'Shaughnessy, I. Choudhary, and J.I. Harper Interleukin-1 alpha blockade prevents hyperkeratosis in an in vitro model of lamellar ichthyosis Hum Mol Genet 19 July (13) 2010 2594 2605
122. E. Ingham, E.A. Eady, C.E. Goodwin, J.H. Cove, and W.J. Cunliffe Pro-inflammatory levels of interleukin-1 alpha-like bioactivity are present in the majority of open comedones in acne vulgaris J Invest Dermatol 98 June (6) 1992 895 901
123. C.A. Dinarello Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist Int Rev Immunol 16 5-6 1998 457 499
124. J. Steinberg, J. Halter, H. Schiller, L. Gatto, D. Carney, and H.M. Lee Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model Shock 24 October (4) 2005 348 356
125. J.A. Vincent, and S. Mohr Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia Diabetes 56 January (1) 2007 224 230
126. A.L. Wang, A.C. Yu, L.T. Lau, C. Lee, M. Wu le, and X. Zhu Minocycline inhibits LPS-induced retinal microglia activation Neurochem Int 47 July (1-2) 2005 152 158 (Pubitemid 40848704)
127. E.A. Eady, E. Ingham, C.E. Walters, J.H. Cove, and W.J. Cunliffe Modulation of comedonal levels of interleukin-1 in acne patients treated with tetracyclines J Invest Dermatol 101 July (1) 1993 86 91
128. T. Kobayashi, J. Kishimoto, Y. Ge, W. Jin, D.L. Hudson, and N. Ouahes A novel mechanism of matrix metalloproteinase-9 gene expression implies a role for keratinization EMBO Rep 2 July (7) 2001 604 608
129. M. Dilly, N. Hambruch, J.D. Haeger, and C. Pfarrer Epidermal growth factor (EGF)induces motility and upregulates MMP-9 and TIMP-1 in bovine trophoblast cells Mol Reprod Dev 77 July (7) 2010 622 629
130. B. Heissig, C. Nishida, Y. Tashiro, Y. Sato, M. Ishihara, and M. Ohki Role of neutrophil-derived matrix metalloproteinase-9 in tissue regeneration Histol Histopathol 25 June (6) 2010 765 770
131. B.C. Melnik Role of FGFR2-signaling in the pathogenesis of acne Dermatoendocrinology 1 May (3) 2009 141 156
132. R. Skidmore, R. Kovach, C. Walker, J. Thomas, M. Bradshaw, and J. Leyden Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne Arch Dermatol 139 April (4) 2003 459 464
133. E. Adien, Y. Kaymak, M.A. Gurer, and E. Durukan Topical tetracycline in the treatment of acne vulgaris J Drugs Dermatol 7 October (10) 2008 953 955
134. J.D. Panzer, W. Poche, T.J. Meek, V.J. Derbes, and W. Atkinson Acne treatment: a comparative efficacy trial of clindamycin and tetracycline Cutis 19 January (1) 1977 109 111
135. E.M. de Jong, C.M. Ferrier, A. de Zwart, P.J. Wauben-Penris, C. Korstanje, and P.C. van de Kerkhof Effects of topical treatment with budesonide on parameters for epidermal proliferation, keratinization and inflammation in psoriasis J Dermatol Sci 9 May (3) 1995 185 194
136. P. Toossi, M. Farshchian, F. Malekzad, N. Mohtasham, and A. Kimyai-Asadi Subantimicrobial-dose doxycycline in the treatment of moderate facial acne J Drugs Dermatol 7 December (12) 2008 1149 1152
137. J.J. Leyden, J.Q. Del Rosso, and G.F. Webster Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance Cutis 79 June (6 Suppl.) 2007 9 25 [review]
138. M. Oka Pyoderma gangrenosum and interleukin 8 Br J Dermatol 157 December (6) 2007 1279 1281 [Epub 2007 October 4]
139. P.R. Cohen Sweet's syndrome - a comprehensive review of an acute febrile neutrophilic dermatosis Orphanet J Rare Dis 2 July (34) 2007 [review]
140. J. Miller, B.A. Yentzer, A. Clark, J.L. Jorizzo, and S.R. Feldman Pyoderma gangrenosum: areview and update on new therapies J Am Acad Dermatol 62 April (4) 2010 646 654 [review]
141. Marzano AV, Cugno M, Trevisan V, Fanoni D, Venegoni L, Berti E, Crosti C. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol 2010 July 16.
142. R.K. Joshi, D.N. Atukorala, A. Abanmi, O. al Khamis, and A. Haleem Successful treatment of Sweet's syndrome with doxycycline Br J Dermatol 128 May (5) 1993 584 586
143. John Berth-Jones Mrcp, Stella Veronica Tan, Robin Alan Charles Graham-Brown, Andrew Charles Pembroke, The successful use of minocycline in pyoderma gangrenosum - a report of seven cases and review of the literature. J Dermatol Treatment June 1989;1(1):23-5.
144. H. Mensing, and L. Kowalzick Acute febrile neutrophilic dermatosis (Sweet's syndrome) caused by minocycline Dermatologica 182 1 1991 43 46
145. M.J. Thibault, R.C. Billick, and H. Srolovitz Minocycline-induced Sweet's syndrome J Am Acad Dermatol 27 November (5 Pt 2) 1992 801 804
146. A. Jamet, L. Lagarce, C. Le Clec'h, A. Croué, F. Hoareau, and B. Diquet Doxycycline-induced Sweet's syndrome Eur J Dermatol 18 September-October (5) 2008 595 596
147. B. Khan Durani, and U. Jappe Drug-induced Sweet's syndrome in acne caused by different tetracyclines: case report and review of the literature Br J Dermatol 147 September (3) 2002 558 562
148. C. van den Bogert, E.H. Blaauw, B.H. Dontje, C.E. Hulstaert, M.J. Hardonk, and A.M. Kroon The effect of doxycycline on polyvinylpyrrolidone- induced granuloma formation in the rat liver Virchows Arch B Cell Pathol Incl Mol Pathol 51 1 1986 39 50
149. N. Myatt, G. Coghill, K. Morrison, D. Jones, and I.A. Cree Detection of tumour necrosis factor alpha in sarcoidosis and tuberculosis granulomas using in situ hybridisation J Clin Pathol 47 1994 423 426
150. H.G. Liu Spirochetes in the cheilits granulomatosa and sarcoidosis Zhonghua Yi Xue Za Zhi 73 March (3) 1993 142 144 189-90
151. C.B. Doherty, and T. Rosen Evidence-based therapy for cutaneous sarcoidosis Drugs 68 10 2008 1361 1383 [review]
152. A. Furukawa, K. Uchida, Y. Ishige, I. Ishige, I. Kobayashi, and T. Takemura Characterization of Propionibacterium acnes isolates from sarcoid and non-sarcoid tissues with special reference to cell invasiveness, serotype, and trigger factor gene polymorphism Microb Pathog 46 February (2) 2009 80 87
153. I. Ishige, Y. Eishi, T. Takemura, I. Kobayashi, K. Nakata, and I. Tanaka Propionibacterium acnes is the most common bacterium commensal in peripheral lung tissue and mediastinal lymph nodes from subjects without sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis. 22 March (1) 2005 33 42
154. T.G. Marshall, and F.E. Marshall Sarcoidosis succumbs to antibiotics - implications for autoimmune disease Autoimmun Rev 3 June (4) 2004 295 300 [review]
155. E. Miyazaki, M. Ando, T. Fukami, S. Nureki, Y. Eishi, and T. Kumamoto Minocycline for the treatment of sarcoidosis: is the mechanism of action immunomodulating or antimicrobial effect? Clin Rheumatol 27 September (9) 2008 1195 1197
156. H. Bachelez, P. Senet, J. Cadranel, A. Kaoukhov, and L. Dubertret The use of tetracyclines for the treatment of sarcoidosis Arch Dermatol 137 January (1) 2001 69 73
157. K. Beer Delayed onset nodules from liquid injectable silicone: report of a case, evaluation of associated histopathology and results of treatment with minocycline and celocoxib J Drugs Dermatol 8 October (10) 2009 952 954
158. M.J. Arin, J. Bäte, T. Krieg, and N. Hunzelmann Silicone granuloma of the face treated with minocycline J Am Acad Dermatol 52 February (2 Suppl. 1) 2005 53 56
159. P. Senet, H. Bachelez, L. Ollivaud, D. Vignon-Pennamen, and L. Dubertret Minocycline for the treatment of cutaneous silicone granulomas Br J Dermatol 140 May (5) 1999 985 987
160. L.H. Christensen Host tissue interaction, fate, and risks of degradable and nondegradable gel fillers Dermatol Surg 35 October (Suppl. 2) 2009 1612 1619 [review]
161. M.A. Hazey, A.J. Van Norman, and D.L. Armistead Melkersson-Rosenthal Syndrome with migraine-like headaches treated with minocycline: a case report and review of the literature W V Med J 105 January-February (1) 2009 15 17
162. C. Bourgeois-Droin, S. Havard, F. Granier, M. Vesse, J.L. Salomon, and J. Furioli Granulomatous cheilitis in two children with sarcoidosis J Am Acad Dermatol 29 November (5 Pt 2) 1993 822 824
163. K.R. Cleary, and J.G. Batsakis Orofacial granulomatosis and Crohn's disease Ann Otol Rhinol Laryngol 105 February (2) 1996 166 167
164. McGrath DS, Doyle C, Bredin CP. The Melkersson Rosenthal syndrome - a differential diagnosis of facial sarcoidosis. Ir J Med Sci 1997.
165. D. Ferriby, B. Pertuzon, J. Clarisse, and P. Vermersch Magnetic resonance imaging of the facial nerve in a case of Melkerson-Rosenthal syndrome Rev Neurol (Paris) 154 June (5) 1998 426 428
166. V. Olivier, J.P. Lacour, J. Castanet, C. Perrin, and J.P. Ortonne Cheilitis granulomatosa in a child Arch Pediatr 7 March (3) 2000 274 277
167. S.R. Walsh, D. Hogg, and P.R. Mydlarski Bullous pemphigoid: from bench to bedside Drugs 65 7 2005 905 926 [review]
168. S. Verraes, W. Hornebeck, M. Polette, L. Borradori, and P. Bernard Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid J Invest Dermatol 117 November (5) 2001 1091 1096
169. Y. Niimi, R. Pawankar, and S. Kawana Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid Int Arch Allergy Immunol 139 2 2006 104 113
170. Liu Z, Shipley JM, Vu TH, Zhou X, Diaz LA, Werb Z, Senior RM: Gelatinase B deficient mice are resistant to experimental bullous pemphigoid. J Exp Med 1998;188:475-82.
171. Stahle-Backdahl M, Inoue M, Giudice GJ, Parks WC, 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J Clin Invest 1994;93:2022-30.
172. Liu Z, Shapiro SD, Zhou X, et al., A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 105:113-123, 2000.
173. Z. Liu, X. Zhou, S.D. Shapiro, J.M. Shipley, S.S. Twining, and L.A. Diaz Werb Z.The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo Cell 102 September (5) 2000 647 655
174. L.M. Golub, R.T. Evans, T.F. McNamara, H.M. Lee, and N.S. Ramamurthy A non-antimicrobial tetracycline inhibits gingival matrix metalloproteinases and bone loss in Porphyromonas gingivalis-induced periodontitis in rats Ann N Y Acad Sci 732 September 1994 96 111
175. K. Brejchova, P. Liskova, J. Cejkova, and K. Jirsova Role of matrix metalloproteinases in recurrent corneal melting Exp Eye Res 90 May (5) 2010 583 590
176. N. Cirillo, A. Dell' Ermo, F. Gombos, and A. Lanza The specific proteolysis hypothesis of pemphigus: does the song remain the same? Med Hypotheses 70 2 2008 333 337
177. S.K. Dresow, C. Sitaru, A. Recke, G.J. Oostingh, D. Zillikens, and B.F. Gibbs IgE autoantibodies against the intracellular domain of BP180 Br J Dermatol 160 February (2) 2009 429 432
178. R. Döpp, E. Schmidt, I. Chimanovitch, M. Leverkus, E.B. Bröcker, and D. Zillikens IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity J Am Acad Dermatol 42 April (4) 2000 577 583
179. R. Ganguly, D.G. Pennock, and R.M. Kluge Inhibition of protein synthesis and lymphokine production by tetracycline Allerg Immunol (Leipz) 30 2 1984 104 109
180. C. Sandler, E. Ekokoski, K.A. Lindstedt, P.J. Vainio, M. Finel, and T. Sorsa Chemically modified tetracycline (CMT)-3 inhibits histamine release and cytokine production in mast cells: possible involvement of protein kinase C Inflamm Res 54 July (7) 2005 304 312
181. K.K. Eklund, and T. Sorsa Tetracycline derivative CMT-3 inhibits cytokine production, degranulation, and proliferation in cultured mouse and human mast cells Ann N Y Acad Sci 878 June 1999 689 691
182. C. Sandler, K. Nurmi, K.A. Lindstedt, T. Sorsa, L.M. Golub, and P.T. Kovanen Eklund KK.Chemically modified tetracyclines induce apoptosis in cultured mast cells Int Immunopharmacol 5 October (11) 2005 1611 1621
183. M.A. Berk, and A.L. Lorincz The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report Arch Dermatol 122 June (6) 1986 670 674
184. C.R. Thornfeldt, and A.W. Menkes Bullous pemphigoid controlled by tetracycline J Am Acad Dermatol 16 February (2 Pt 1) 1987 305 310
185. I. Thomas, S. Khorenian, and D.M. Arbesfeld Treatment of generalized bullous pemphigoid with oral tetracycline J Am Acad Dermatol 28 January (1) 1993 74 77
186. D.P. Fivenson, D.L. Breneman, G.B. Rosen, C.S. Hersh, S. Cardone, and D. Mutasim Nicotinamide and tetracycline therapy of bullous pemphigoid Arch Dermatol 130 June (6) 1994 753 758
187. E. Sánchez Miralles, M. Nuñez Cabezón, and A. Ledo Pozueta Treatment of generalized bullous pemphigoid with oral tetracycline J Am Acad Dermatol 30 February (2 Pt 1) 1994 291
188. L. Reiche, F. Wojnarowska, and E. Mallon Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy Clin Exp Dermatol 23 November (6) 1998 254 257
189. J. Shiohara, K. Yoshida, J. Hasegawa, H. Uhara, M. Takata, T. Saida, B. Oyama, and T. Hashimoto Tetracycline and niacinamide control bullous pemphigoid but not pemphigus foliaceus when these conditions coexist J Dermatol 37 Jul (7) 2010 657 661
190. A.T. Goon, S.H. Tan, L.S. Khoo, and T. Tan Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore Singapore Med J 41 July (7) 2000 327 330
191. Loo WJ, Kirtschig G, Wojnarowska F. Minocycline as a therapeutic option in bullous pemphigoid. Clin Exp Dermatol 2001 July;26(5):376-9.
192. E. Alpsoy, E. Yilmaz, E. Basaran, S. Yazar, and L. Cetin Is the combination of tetracycline and nicotinamide therapy alone effective in pemphigus? Arch Dermatol 131 November (11) 1995 1339 1340
193. A. Calebotta, A.M. Sáenz, F. González, M. Carvalho, and R. Castillo Pemphigus vulgaris:benefits of tetracycline as adjuvant therapy in a series of thirteen patients Int J Dermatol 38 March (3) 1999 217 221
194. M.L. Chaffins, D. Collison, and D.P. Fivenson Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases J Am Acad Dermatol 28 June (6) 1993 998 1000
195. D.P. Fivenson, and T.L. Kimbrough Lichen planus pemphigoides: combination therapy with tetracycline and nicotinamide J Am Acad Dermatol 36 April (4) 1997 638 640
196. M. Laimer, C.M. Lanschützer, E. Nischler, A. Klausegger, A. Diem, and G. Pohla-Gubo Hereditary blistering diseases. Symptoms, diagnosis and treatment of epidermolysis bullosa Hautarzt 60 May (5) 2009 378 388 [review]
197. D. Sawamura, T. Sugawara, I. Hashimoto, L. Bruckner-Tuderman, D. Fujimoto, and Y. Okada Increased gene expression of matrix metalloproteinase- 3(stromelysin) in skin fibroblasts from patients with severe recessive dystrophic epidermolysis bullosa Biochem Biophys Res Commun 174 January (2) 1991 1003 1008
198. J.S. Kern, G. Grüninger, R. Imsak, M.L. Müller, H. Schumann, and D. Kiritsi Forty-two novel COL7A1mutations and the role of a frequent single nucleotide polymorphism in the MMP1promoter in modulation of disease severity in a large European dystrophic epidermolysis bullosa cohort Br J Dermatol 161 November (5) 2009 1089 1097
199. M. Titeux, V. Pendaries, L. Tonasso, A. Décha, C. Bodemer, and A. Hovnanian A frequent functional SNP in the MMP1 promoter is associated with higher disease severity in recessive dystrophic epidermolysis bullosa Hum Mutat 29 February (2) 2008 267 276
200. J.E. White Minocycline for dystrophic epidermolysis bullosa Lancet 1 April (8644) 1989 966
201. S.M. Langan, and H.C. Williams A systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa Clin Exp Dermatol 34 January (1) 2009 20 25 [Epub 2008 September 25]
202. S.K. Hansen, and N.K. Veien Oxytetracycline in epidermolysis bullosa simplex. A double-blind placebo-controlled trial J Eur Acad Dermatol Venereol 6 1996 277 278
203. Retief CR, Malkinson FD, Pearson RW. Two familial cases of epidermolysis bullosa simplex successfully treated with tetracycline. Arch Dermatol 1999 August;135(8):997-8 [Erratum in: Arch Dermatol 1999 November;135(11):1333].
204. M. Weiner, A. Stein, S. Cash, J. de Leoz, and J.D. Fine Tetracycline and epidermolysis bullosa simplex: a double-blind, placebo-controlled, crossover randomized clinical trial Br J Dermatol 150 March (3) 2004 613 614
205. Lundqvist K, Sørensen OE, Schmidtchen A. Increased levels of human neutrophil alpha-defensins in chronic venous leg ulcers. J Dermatol Sci 2008 August; 51(2):131-4 [Epub 2008 May 9].
206. U. Schönfelder, M. Abel, C. Wiegand, D. Klemm, P. Elsner, and U.C. Hipler Influence of selected wound dressings on PMN elastase in chronic wound fluid and their antioxidative potential in vitro Biomaterials 26 November (33) 2005 6664 6673
207. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F, Murphy G, Schultz G., Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen. 1999 November-December;7(6):442-52.
208. A.B. Wysocki, L. Staiano-Coico, and F. Grinnell Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9 J Invest Dermatol 101 July (1) 1993 64 68
209. Yager DR, Zhang LY, Liang HX, Diegelmann RF, Cohen IK.Rayment EA, Upton Z, Shooter GK. Br J Dermatol 2008 May;158(5):951-61. Epub 2008 February 16. Increased matrix metalloproteinase-9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer.
210. Widgerow AD. Nanocrystalline silver, gelatinases and the clinical implications. Burns 2010 April 13.
211. Stechmiller J, Cowan L, Schultz G. The Role of Doxycycline as a Matrix Metalloproteinase Inhibitor for the Treatment of Chronic Wounds. Biol Res Nurs. 2009 December 22 [Epub ahead of print].
212. N.J. Trengove, H. Bielefeldt-Ohmann, and M.C. Stacey Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers Wound Repair Regen 8 January-February (1) 2000 13 25
213. Rayment EA, Upton Z, Shooter GK., Br J Dermatol 2008 May;158(5):951-61. Epub 2008 February 16. Increased matrix metalloproteinase-9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer.
214. G.P. Ladwig, M.C. Robson, R. Liu, M.A. Kuhn, D.F. Muir, and G.S. Schultz Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers Wound Repair Regen 10 January-February (1) 2002 26 37
215. J. Mackelfresh, S. Soon, and J.L. Arbiser Combination therapy of doxycycline and topical tacrolimus for venous ulcers Arch Dermatol 141 November (11) 2005 1476 1477
216. J.L. Arbiser Angiogenesis and the skin: a primer J Am Acad Dermatol 34 1996 486 497
217. G.A. Chin, T.G. Thigpin, K.J. Perrin, L.L. Moldawer, and Schultz Treatment of chronic ulcers in diabetic patients with a topical metalloproteinase inhibitor, doxycycline Wounds October 2003 315 323
218. Stechmiller J, Cowan L, Schultz G. The Role of Doxycycline as a Matrix Metalloproteinase Inhibitor for the Treatment of Chronic Wounds. Biol Res Nurs. 2009 December 22.
219. K. Penhallow A review of studies that examine the impact of infection on the normal wound-healing process J Wound Care 14 March (3) 2005 123 126 [review]
220. N.S. Ramamurthy, A.J. Kucine, S.A. McClain, T.F. McNamara, and L.M. Golub Topically applied CMT-2 enhances wound healing in streptozotocin diabetic rat skin Adv Dent Res 12 November (2) 1998 144 148
221. Hall JC, Hall BJ. Human Herpes Virus 8: Kaposi's Sarcoma from chapter Common Viral Infections in Skin Infections: Diagnosis and Treatment. pp. 33-34 Cambridge University Press. 2009.
222. M.R. Bongiorno, S. Doukaki, G. Ferro, and M. Aric Matrix metalloproteinases 2 and 9,and extracellular matrix in Kaposi's sarcoma Dermatol Ther 23 March-April (Suppl. 2) 2010 S33 S36
223. L. Pantanowitz, B.J. Dezube, S. Hernandez-Barrantes, S.R. Tahan, and M.K. Dabbous Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma J Cutan Pathol 33 December (12) 2006 793 798
224. B. Shan, C.A. Morris, Y. Zhuo, B.D. Shelby, D.R. Levy, and J.A. Lasky Activation of proMMP-2 and Src by HHV8 vGPCR in human pulmonary arterial endothelial cells J Mol Cell Cardiol 42 March (3) 2007 517 525
225. C.J. Barnstable, and J. Tombran-Tink Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential Prog Retin Eye Res. 23 September (5) 2004 561 577
226. Bower M, Weir J, Francis N, Newsom-Davis T, Powles S, Crook T, Boffito M,Gazzard B, Nelson M. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. AIDS 2009 August 24;23(13):1701-6.
227. L. Feller, C. Anagnostopoulos, N.H. Wood, M. Bouckaert, E.J. Raubenheimer, and J. Lemmer Human immunodeficiency virus-associated Kaposi sarcoma as an immune reconstitution inflammatory syndrome: a literature review and case report J Periodontol 79 February (2) 2008 362 368
228. B.J. Dezube, S.E. Krown, J.Y. Lee, K.S. Bauer, and D.M. Aboulafia Randomized phase II trialof matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study J Clin Oncol 24 March (9) 2006 1389 1394
229. B.M. Hantash, and M.H. Kanzler The efficacy of tetracycline antibiotics for treatment of lichen planus: an open-label clinical trial Br J Dermatol 156 April (4) 2007 758 760
230. M. Walchner, G. Messer, N. Salomon, G. Plewig, and M. Röcken Topical tetracycline treatment of erosive oral lichen planus Arch Dermatol 135 January (1) 1999 92 93
231. N. Tsankov, S. Vassileva, and A. Lazarova Onset of psoriasis coincident with tetracycline therapy Aust J Dermatol 29 1988 111 112
232. N. Tsankov, N. Botev-Zlatkov, and A. Lazarova Psoriasis and drugs: influence of tetracyclines on the course of psoriasis J Am Acad Dermatol 19 1988 629 632
233. T. Bergner, and B. Przybilla Psoriasis and tetracyclines J Am Acad Dermatol 23 October (4 Pt 1) 1990 770 771
234. F. Rongioletti, C. Fiorucci, and A. Parodi Psoriasis induced or aggravated by drugs J Rheumatol Suppl 83 August 2009 59 61
235. Jones HE, Lewis CW, Reisner JE. Photosensitive lichenoid eruption associated with demeclocycline. Arch Dermatol 1972;106:58-63.
236. H.I. Maibach, J. Epstein, and M. Sams Photosensitive lichenoid eruption associated with demeclocycline Arch Dermatol 109 1974 97 98
237. M. Bjellerup, and B. Ljunggren Double blind cross-over studies on phototoxicity to three tetracycline derivatives in human volunteers Photodermatology 4 December (6) 1987 281 287
238. T. Badri, N. Ben Tekaya, F. Cherif, and A. Ben Osman Dhahri Photo-onycholysis: two cases induced by doxycycline Acta Dermatovenerol Alp Panonica Adriat 13 December (4) 2004 135 136
239. R.W. Mouton, H.F. Jordaan, and J.W. Schneider A new type of minocycline-induced cutaneous hyperpigmentation Clin Exp Dermatol 29 January (1) 2004 8 14
240. A.M. Layton, and W.J. Cunliffe Phototoxic eruptions due to doxycycline - a dose-related phenomenon Clin Exp Dermatol 18 September (5) 1993 425 427
241. D.S. Lim, and G.M. Murphy High-level ultraviolet A photoprotection is needed to prevent doxycycline phototoxicity: lessons learned in East Timor Br J Dermatol 149 July (1) 2003 213 214
242. B.T. Fay, A.P. Whiddon, S. Puumala, N.A. Black, J.R. O'Dell, and T.R. Mikuls Minocycline-induced hyperpigmentation in rheumatoid arthritis J Clin Rheumatol 14 February (1) 2008 17 20
243. N.E. Fiehn, and J. Westergaard Doxycycline-resistant bacteria in periodontally diseased individuals after systemic doxycycline therapy and in healthy individuals Oral Microbiol Immunol 5 August (4) 1990 219 222
244. J.K. Moller, A.L. Bak, A. Stenderup, H. Zachariae, and H. Afzelius Changing patterns of plasmid-mediated drug resistance during tetracycline therapy Antimicrob Agents Chemother 11 March (3) 1977 388 391
245. A.F. Chambers, and L.M. Matrisian Changing views of the role of matrix metalloproteinases in metastasis J Natl Cancer Inst 89 September (17) 1997 1260 1270